New phase II study supports potential of gs-9450 as new treatment option for steatohepatitis
Friday, April 16, 2010 - 10:22
in Health & Medicine
Results from a multinational phase II study presented today at the International Liver Congress 2010 have shown that treatment with the caspase inhibitor GS-9450 can reduce markers of liver damage in patients with non-alcoholic steatohepatitis (NASH - the most serious form of non-alcoholic liver disease) as demonstrated by reduced levels of alanine (ALT) and aspartate aminotransferases (AST), hepatic enzymes that indicate cell damage.